Extended Letrozole Sustains DFS Benefit at 15 Years in HR+ Breast Cancer - 九游游戏

Extending letrozole (Femara) for 5 additional years showed a statistically significant improvement in disease-free survival (DFS) vs placebo in postmenopausal patients with hormone receptor (HR)-positive breast cancer who had completed prior adjuvant... [6224 chars]